Anlon Healthcare Limited Plans New Marketing Office in Ahmedabad

Anlon Healthcare Limited has announced plans to establish a new marketing office in Ahmedabad, Gujarat, marking a significant step in the company's expansion strategy. The announcement was made through a regulatory filing under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Business Expansion Details

Anlon Healthcare Limited disclosed its intention to open the marketing office in Ahmedabad in the near future, though specific timelines were not provided in the announcement. This expansion move appears to be part of the company's strategy to strengthen its market presence in the Gujarat region.

Parameter	Details
Location	Ahmedabad, Gujarat
Office Type	Marketing Office
Timeline	Near Future
Purpose	Business Expansion

Regulatory Compliance

The disclosure was made in compliance with the listing regulations, demonstrating Anlon Healthcare's commitment to maintaining transparency with stakeholders and regulatory authorities. The company has assured that it will provide further updates as developments progress regarding this new facility.

Company Background

Anlon Healthcare Limited operates in the chemicals sector and is registered in Gujarat. The company's registered office is located at 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat. Anlon Healthcare maintains its commitment to keeping stakeholders informed about significant business developments through proper regulatory channels.

The establishment of a marketing office in Ahmedabad represents the company's strategic focus on expanding its operational footprint within Gujarat, potentially enhancing its market reach and customer engagement capabilities in the region.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.32%	-0.70%	-10.96%	+50.96%	+50.96%	+50.96%

Anlon Healthcare Limited released its unaudited standalone financial results for the first quarter of fiscal year 2026, covering the period ended June 30, 2025. The pharmaceutical company, which specializes in manufacturing Active Pharmaceutical Ingredients (APIs) and drug intermediates, demonstrated mixed performance with maintained profitability despite revenue challenges.

Financial Performance Overview

Anlon Healthcare reported a net profit of ₹354.69 lacs for Q1FY26, down from ₹376.35 lacs in Q1FY25. The company's revenue declined by 12% year-over-year to ₹3,329.72 lacs. Despite the revenue decrease, the company showed strong operational efficiency improvements.

The company's financial metrics for Q1FY26 showed both strengths and areas of concern when compared to the corresponding quarter of the previous year:

Metric	Q1FY26	Q1FY25	Change (%)
Revenue from Operations	3329.72	3783.25	-12.0%
Total Income	3330.89	3789.34	-12.1%
Total Expenses	2830.48	3236.83	-12.6%
Profit Before Tax	500.41	552.51	-9.4%
Net Profit After Tax	354.69	376.35	-5.8%
Earnings Per Share (Basic)	2.22	0.41	+441.5%

Revenue and Operational Analysis

Revenue from operations declined by 12.0% year-on-year to ₹3,329.72 lacs in Q1FY26 from ₹3,783.25 lacs in Q1FY25. Other income remained minimal at ₹1.17 lacs compared to ₹6.09 lacs in the previous year quarter. The company's total income decreased to ₹3,330.89 lacs from ₹3,789.34 lacs, reflecting the challenging market conditions in the pharmaceutical sector.

Cost Management and Profitability

Despite the revenue decline, Anlon Healthcare demonstrated effective cost management strategies. Total expenses decreased by 12.6% to ₹2,830.48 lacs from ₹3,236.83 lacs in Q1FY25. Key expense components showed the following changes:

Cost of materials consumed increased to ₹2,959.48 lacs from ₹1,949.10 lacs
Employee benefits expense rose to ₹122.49 lacs from ₹116.41 lacs
Finance costs decreased to ₹81.71 lacs from ₹98.39 lacs
Other expenses declined to ₹161.31 lacs from ₹201.92 lacs

Balance Sheet Strength

The company's balance sheet as of June 30, 2025, showed total assets of ₹19,775.76 lacs compared to ₹18,129.99 lacs as of March 31, 2025. Total equity increased to ₹8,396.86 lacs from ₹8,042.17 lacs, indicating strengthened shareholder value. Current assets grew significantly to ₹17,534.74 lacs from ₹15,848.09 lacs, primarily driven by increased trade receivables and inventory levels.

Cash Flow and Liquidity Position

Anlon Healthcare generated positive cash flow from operating activities of ₹117.88 lacs during the quarter. The company maintained adequate liquidity with cash and cash equivalents of ₹185.67 lacs as of June 30, 2025, compared to ₹144.96 lacs at the beginning of the period. Net cash used in financing activities was ₹74.37 lacs, while investing activities consumed ₹2.80 lacs.

Earnings Per Share Performance

Notably, the company's earnings per share showed remarkable improvement, rising to ₹2.22 in Q1FY26 from ₹0.41 in Q1FY25. This significant increase reflects the company's focus on operational efficiency and cost optimization despite the challenging revenue environment. Both basic and diluted earnings per share remained at ₹2.22 for the quarter.